Press "Enter" to skip to content

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

The results showed the drug, Bavencio, in combination with, or as a follow-on treatment to, platinum-based chemotherapy could not achieve the primary goal of progression-fee survival in patients.

Original source: https://health.economictimes.indiatimes.com/news/pharma/merck-kgaa-pfizer-to-end-late-stage-ovarian-cancer-treatment-study/67202298?utm_source=RSS&utm_medium=ETRSS

Also Read:   Germany wards off US virus vaccine interest